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To the Editor: We developed a form of thermal therapy, namely
“Waon therapy” (soothing warm therapy) (1), which differs from
the traditional sauna, and demonstrated that the repeated use of a
dry sauna at 60°C improves hemodynamics and ameliorates symp-
toms and vascular function in patients with chronic heart failure
(2,3). Nitric oxide (NO), constitutively produced by endothelial
nitric oxide synthase (eNOS), is a mediator of angiogenesis.
Recently, we reported that repeated Waon therapy increases eNOS
protein expression, blood flow, and capillary density in a mouse
model of hind limb ischemia (4). Furthermore, Waon therapy does
not increase blood flow and capillary density in eNOS-deficient
mice, and we conclude that eNOS is a critical regulator of
angiogenesis by Waon therapy.
Peripheral arterial disease (PAD) is a major cause of acute and
chronic illness, associated with decrements in functional capacity
and quality of life. We conducted this study to evaluate the
beneficial effect of repeated Waon therapy using infrared-ray dry
sauna on patients with PAD.
Patients were qualified for Waon therapy if they had chronic
limb ischemia, including claudication, rest pain, and/or nonhealing
ischemic ulcers present for a minimum of 4 weeks without
evidence of improvement in spite of conventional therapies and
were not candidates for surgical or nonsurgical revasculariza-
tion. Requisite hemodynamic deficits included a resting ankle-
brachial pressure index (ABI) 0.9 in the affected limb on 2
consecutive examinations performed at least 1 week apart. We
enrolled 20 patients with PAD, including 15 patients with
bilateral limb ischemia and 5 patients with unilateral limb
ischemia.
The patients were placed in a far infrared-ray dry sauna, in
which the temperature was evenly maintained at 60°C for 15 min,
and then were kept on a bed outside the sauna for additional 30
min with sufficient warmth provided by blankets (2). They were
weighed before and after Waon therapy, and oral hydration with
water was used to compensate for weight loss. This Waon therapy
was performed once a day for 5 days per week for a period of 10
weeks. Data were compared using paired t tests.
All patients enrolled in the trial completed the study without
any adverse events. The demographic and clinical data of patients
treated with 10-week Waon therapy are summarized in Table 1.
Therapeutic benefit was demonstrated by regression of rest pain in
all patients. Ischemic ulcers healed in all of the 7 limbs, resulting
in successful limb salvage.
Leg pain was scored by a visual analog scale, using a marked
10-cm line extending from “no pain: 0” to “severe pain: 10.” The
pain score significantly decreased after 10 weeks of Waon therapy
(Fig. 1A). Exercise performance, evaluated by the 6-min walking
distance, improved in all 18 patients after 10 weeks of Waon
therapy (Fig. 1B). We measured the ABI in 31 limbs, and the
mean ABI significantly increased after Waon therapy (Fig. 1C).
Serial assessment of leg blood flow was performed with laser
Doppler imaging. It showed that blood flow increased after 10
weeks (Fig. 1D). Digital subtraction angiography was performed
to evaluate new collateral vessel formation in 20 legs (13 patients),
which showed a dramatic increase in the visible collateral vessels in
12 ischemic legs after 10 weeks of Waon therapy.
In summary, we have shown that repeated Waon therapy is safe
for patients with severe PAD and potentially effective as evidenced
by a substantial decrease in the pain score, increases in ABI and
blood flow assessed by laser Doppler perfusion imaging, and by
formation of new collateral vessels on angiography. In addition,
ischemic ulcers present in 7 limbs healed or improved markedly.
Given the poor prognosis of patients with chronic critical limb
ischemia in whom the possibility of spontaneous improvement is
remote, the outcome in this study is encouraging.
We reported that angiogenesis was induced via eNOS using
Waon therapy in mice with hind limb ischemia (4). Nitric oxide is
a mediator of angiogenesis and plays a key role in angiogenesis
induced by Waon therapy. Repeated Waon therapy increases
cardiac output, shear stress of the vessel wall, and ultimately eNOS
expression.
Aicher et al. (5) reported that the impaired neovascularization in
mice lacking eNOS is related to a defect in progenitor cell
mobilization, and eNOS is essential for mobilization of stem and
progenitor cells. We believe that our Waon therapy increases the
number of circulating endothelial progenitor cells via partially
NO-dependent. This may contribute to angiogenesis in patients
with PAD, who are characterized by a reduced systemic NO
bioactivity.
Exercise also increases circulating endothelial progenitor cells,
and supervised exercise training is recommended as an initial
treatment modality for patients with intermittent claudication.
The advantage of Waon therapy compared with exercise therapy
for PAD is that we can successfully perform Waon therapy in
patients who cannot exercise. Combinations of Waon therapy
and exercise training might be useful for patients with PAD.
Cellular and molecular therapeutic modalities for PAD have
shown early efficacy. Therefore, we should analyze the syner-
gistic effect of Waon therapy and gene transfer or therapeutic
stem cell therapy.
We recently described one of the impressive patients (Patient
#13 in Table 1) (6). His large skin ulcer healed completely after
15 weeks of Waon therapy, and limb amputation was avoided.
In addition, 10 of 20 patients in this study were followed at our
outpatient clinic and they continued Waon therapy at least
twice per week. In the follow-up period ranging from 6 months
to 3 years, none of them showed the worsening symptoms of PAD.
Therefore, to maintain the effect of Waon therapy, we believe that
treatment should be continued at least twice per week after
discharge.
The limitation of this study is the lack of a control group. In the
absence of a control group, the treatment effect cannot be esti-
mated, confounding standard care variables are not defined, and
enrollment bias could lead to comparable rates of clinical improve-
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ment. Randomized and controlled trials with larger numbers of
patients with PAD will help to determine the efficacy of Waon
therapy.
In conclusion, we demonstrated that Waon therapy improved
symptoms, status, and blood flow in patients with PAD. Our
Waon therapy method may therefore be a novel innovative therapy
for patients with PAD.
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Figure 1 Improvement in Pain, Walking, ABI, and Blood
Flow After 10 Weeks of Waon Therapy
(A) Pain score evaluated by a visual analog scale (10  severe pain, 0  no
pain) (n  20); (B) 6-min walking distance (n  18); (C) ankle-brachial pres-
sure index (ABI) (n  31); and (D) laser Doppler perfusion imaging (n  28).
p  0.01.
Clinical Data Before and After Waon Therapy
Table 1 Clinical Data Before and After Waon Therapy
Clinical History and Findings Before Waon Therapy Outcome After Waon Therapy
Patient
# Gender
Age
(yrs) Smoking DM
Previous
Surgery Signs/Symptoms Limb Status ABI
1 F 79   None Leg ulcer Leg ulcer completely healed Rt 0.76¡0.86/Lt 0.70¡0.82
2 M 63   None Leg ulcer Toe ulcer
(digits I, II)
Leg ulcer completely healed
Toe ulcer improved
Rt Im/Lt Im
3 M 70   Below knee
amputation
F-F bypass
Rest pain Rest pain resolved Rt Im/Lt 0.60¡0.74
4 M 75   None Intermittent claudication Walking distance increased Rt 0.68¡0.79/Lt 0.82¡0.95
5 F 82   None Intermittent claudication Walking distance increased Rt 0.56¡0.64/Lt 0.74¡0.76
6 F 72   None Rest pain Rest pain resolved Rt 0.76¡0.70/Lt 1.05¡1.03
7 M 80   None Intermittent claudication Walking distance increased Rt 0.30¡0.40/Lt 0.82¡0.84
8 F 88   None Rest pain Rest pain resolved Rt 0.54¡0.60/Lt 0.75¡0.60
9 M 77   None Toe ulcer (digit II) Toe ulcer improved Rt 0.64¡0.72/Lt 0.98¡1.02
10 M 75   None Intermittent claudication Walking distance increased Rt 0.55¡0.61/Lt 0.50¡0.56
11 M 76   None Intermittent claudication Walking distance increased Rt 0.65¡0.74/Lt 0.38¡0.54
12 M 80   None Toe ulcer (digit I) Toe ulcer improved Rt Im/Lt 0.30¡0.55
13 M 64   Toe amputation
F-P bypass,
P-T bypass
Toe ulcer Toe ulcer completely healed Rt Im¡0.37/Lt 0.81¡0.85
14 M 66   Toe amputation
F-P bypass
Toe ulcer Toe ulcer completely healed Rt 0.74¡0.74/Lt 0.79¡0.79
15 M 73   None Intermittent claudication Walking distance increased Rt 0.63¡0.81/Lt 0.64¡0.82
16 M 66   Toe amputation
F-P bypass
Rest pain Rest pain resolved Rt Im/Lt 1.01¡1.00
17 M 73   None Intermittent claudication Walking distance increased Rt 0.44¡0.44/Lt 0.45¡0.46
18 F 79   None Intermittent claudication Walking distance increased Rt 0.54¡0.65/Lt 0.51¡0.52
19 M 81   None Intermittent claudication Walking distance increased Rt 0.48¡0.49/Lt 0.49¡0.50
20 M 68   None Intermittent claudication Walking distance increased Rt 0.51¡0.55/Lt 1.10¡1.10
ABI  ankle brachial pressure index; DM  diabetes mellitus; F-F  femoral-femoral artery; F-P  femoral-popliteal artery; Im  impossible to measure; Lt  left; P-T  popliteal-tibial artery; Rt  right.
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Letters to the Editor
Complex Roles of Endothelial
Shear Stress in Vascular
Remodeling Response
With great interest I read the review article by Chatzizisis et al. (1)
regarding endothelial shear stress (ESS), coronary atherosclerosis,
and vascular remodeling. The authors stated in the text, “Recent
observations, however, indicate that low ESS leads to excessive
expansive remodeling . . .” from their diabetic hyperlipidemic
swine model. However, in their previous human study (2), they
demonstrated that constrictive remodeling occurred more fre-
quently (44%) than expansive remodeling (22%) in subsegments
with low ESS, whereas expansive remodeling occurred more
frequently (26.3%) than constrictive remodeling (5.3%) in subseg-
ments with moderate/higher ESS. These results suggest complex
roles of ESS in the vascular remodeling response, depending on
concomitant conditions including atherosclerotic stage, in addition
to differences in biology between experimental models and clinical
studies (3,4). Further clinical studies are warranted to determine
the role of ESS in vascular remodeling in humans.
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Reply
Dr. Kaneda appropriately draws attention to the complexity of
vascular remodeling. The magnitude of low endothelial shear stress
(ESS), as well as changes in ESS and the rate of change in ESS,
all contribute to the pathobiology of atherosclerosis (1,2). In our
human pilot study, we observed expansive remodeling in areas of
initially low or high ESS. It is therefore likely that expansive
remodeling occurs through different mechanisms in different local
environments and under different flow regimes (3).
Low ESS enhances lipid accumulation and local inflammation.
The enzymatic degradation of the underlying internal elastic
lamina and media that follow ultimately lead to expansive remod-
eling (1). Whether the expansive remodeling response becomes
excessive or compensatory is likely dependent on the magnitude of
low ESS (1). Very low ESS induces an intense inflammatory
response that leads to excessive lumen and wall expansion (exces-
sive expansive remodeling) (1). These wall changes further reduce
local ESS, establishing a cascade of inflammation and excessive
expansive remodeling, which can transform a stable plaque into a
thin cap fibroatheroma. In contrast, in areas with limited reduc-
tions in ESS, local inflammation is modest, and the cellular
reaction might strengthen the plaque and lead to compensatory
expansive remodeling (1). The changes in the vessel wall and the
minimal narrowing of the lumen might restore ESS to more
physiologic levels and thereby promote plaque quiescence.
High ESS might also lead to expansive remodeling, but through
a different mechanism. Reactive dilation of the plaque-free wall
with normal flow-responsive endothelium in the area of an
eccentric plaque can normalize the local ESS environment (4).
In our human pilot study (3), we observed that areas with low
baseline ESS can develop constrictive remodeling at follow-up.
Although the pathobiologic mechanisms responsible for constric-
tive remodeling are less clear than those of expansive remodeling,
constrictive remodeling in our patients may have been related to
subclinical plaque microrupture and subsequent healing (5). Alter-
natively, a fibroproliferative smooth-muscle cell phenotype may
have been consistently operative throughout the natural history
course of that plaque.
We agree that it is critical to understand these vascular behavior
patterns in more detail because the ultimate clinical manifestations
of coronary disease depend on the morphologic evolution and flow
remodeling of the atherosclerotic plaque (1). Although clinical
studies are essential to the identification of atherosclerotic patterns,
animal models enable specific delineation of the dynamic and
2171JACC Vol. 50, No. 22, 2007 Correspondence
November 27, 2007:2169–72
